學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Bellamy's Turnaround in China
內容大綱
Set in December 2017, the case discusses Bellamy's Australia Limited (BAL)'s debacle in China, and its subsequent turnaround. BAL was the leading supplier of infant milk formula and baby food products in China, its largest export market. In mid-2016, the Chinese government, in a bid to control the growing proliferation of sub-quality products in the industry and boost consumer confidence, introduced new import regulations. These regulations restricted all companies, domestic and foreign, to selling a maximum of three product lines, and mandated their pre-approval and registration with the Certification and Accreditation Administration of the People's Republic of China (CNCA) and China Food & Drug Administration (CFDA). BAL's top management's subsequent liquidation of part of their shares in the market, coupled with an attempt to mislead the shareholders regarding the impact of the new regulations on the company's sales in the country, triggered a strong negative investor sentiment. BAL's stock prices plummeted by more than 40% overnight, leading to the company requesting for a voluntary trading suspension of its shares at the Australian Securities Exchange (ASX). In January 2017, the board of directors undertook a series of corrective steps including the appointment of Andrew Cohen as the new CEO. By December 2017, the market situation had improved with BAL reporting reduced inventory, positive operating cash-flow, renewed momentum in sales and a significant improvement in investor outlook. BAL's share price picked up by 60%. Yet, there were many concerns going forward. Would BAL be able to sustain and build upon the positive results, given the highly sensitive nature of the infant milk formula and baby foods industry in addition to the complex legal structure and bureaucracy of the Chinese market? What would be a prudent financial accounting and reporting strategy for BAL management to pursue in order to rebuild its market credibility?